Selected article for: "diagnosis disease risk and disease risk"
Author: Weidmann, Maxwell D; Ofori, Kenneth; Rai, Alex J
Title: Laboratory Biomarkers in the Management of Patients With COVID-19
  • Cord-id: 0bwhl3pe
  • Document date: 2020_10_27
    • ID: 0bwhl3pe
    Snippet: OBJECTIVES: Laboratory testing and the measurement of appropriate biomarkers play a critical role in managing patients with coronavirus disease 2019 (COVID-19), allowing for disease diagnosis, monitoring progression, prognostication, prediction of treatment response, and risk stratification. We sought to characterize these effects on a more detailed, mechanistic level. METHODS: We reviewed the literature and identified a multitude of reports that describe the unique effects of this virus and its
    Document: OBJECTIVES: Laboratory testing and the measurement of appropriate biomarkers play a critical role in managing patients with coronavirus disease 2019 (COVID-19), allowing for disease diagnosis, monitoring progression, prognostication, prediction of treatment response, and risk stratification. We sought to characterize these effects on a more detailed, mechanistic level. METHODS: We reviewed the literature and identified a multitude of reports that describe the unique effects of this virus and its devastating consequences to multiple organ systems in COVID-19 patients. RESULTS: There are specific alterations in biomarkers related to coagulation, depopulation of T-cell subtypes, the cytokine storm and inflammation, and kidney and cardiac dysfunction. CONCLUSIONS: Laboratory measurement of specific parameters and the use of appropriate prognostic, predictive, and monitoring biomarkers afford clinicians the ability to make informed medical decisions and guide therapy for patients afflicted with this dreaded disease.

    Search related documents:
    Co phrase search for related documents
    • activator inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activator inhibitor and acute lung: 1, 2, 3, 4
    • activator inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • activator inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activator inhibitor and adaptive immune response: 1
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adaptive immune response mount: 1
    • acute ards respiratory distress syndrome and adaptive immune system: 1, 2, 3, 4
    • acute cardiac injury and adaptive immune system: 1
    • acute deterioration and additional assessment: 1
    • acute lung and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute lung and adaptive immune system: 1, 2, 3, 4
    • acute phase and adaptive cellular immunity: 1, 2
    • acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and adaptive immune system: 1, 2, 3, 4
    • acute respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute respiratory distress syndrome and adaptive immune response mount: 1
    • acute respiratory distress syndrome and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory distress syndrome and additional cytokine: 1